Adaptimmune Therapeutics Past Earnings Performance
Past criteria checks 0/6
Adaptimmune Therapeutics's earnings have been declining at an average annual rate of -2.4%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been growing at an average rate of 24.6% per year.
Key information
-2.4%
Earnings growth rate
9.9%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 24.6% |
| Return on equity | -288.2% |
| Net Margin | -188.9% |
| Next Earnings Update | 15 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Adaptimmune Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 60 | -114 | 72 | 0 |
| 30 Sep 23 | 71 | -95 | 68 | -11 |
| 30 Jun 23 | 71 | -91 | 69 | 0 |
| 31 Mar 23 | 71 | -114 | 63 | 0 |
| 31 Dec 22 | 27 | -165 | 61 | 0 |
| 30 Sep 22 | 18 | -175 | 63 | 105 |
| 30 Jun 22 | 12 | -176 | 61 | 0 |
| 31 Mar 22 | 9 | -171 | 60 | 0 |
| 31 Dec 21 | 6 | -158 | 57 | 0 |
| 30 Sep 21 | 6 | -156 | 56 | 0 |
| 30 Jun 21 | 6 | -149 | 54 | 0 |
| 31 Mar 21 | 4 | -140 | 50 | 0 |
| 31 Dec 20 | 4 | -130 | 46 | 0 |
| 30 Sep 20 | 3 | -123 | 43 | 0 |
| 30 Jun 20 | 2 | -127 | 41 | 0 |
| 31 Mar 20 | 2 | -138 | 41 | 0 |
| 31 Dec 19 | 1 | -137 | 43 | 0 |
| 30 Sep 19 | 2 | -144 | 43 | 0 |
| 30 Jun 19 | 42 | -99 | 43 | 0 |
| 31 Mar 19 | 51 | -102 | 44 | 0 |
| 31 Dec 18 | 60 | -96 | 44 | 0 |
| 30 Sep 18 | 62 | -87 | 42 | 0 |
| 30 Jun 18 | 49 | -93 | 39 | 0 |
| 31 Mar 18 | 43 | -69 | 36 | -19 |
| 31 Dec 17 | 38 | -70 | 31 | 0 |
| 30 Sep 17 | 42 | -58 | 29 | 17 |
| 30 Jun 17 | 17 | -76 | 26 | 32 |
| 31 Mar 17 | 14 | -78 | 24 | 68 |
| 31 Dec 16 | 14 | -72 | 23 | 0 |
| 30 Sep 16 | 10 | -73 | 23 | 63 |
| 30 Jun 16 | 12 | -61 | 21 | 57 |
| 31 Mar 16 | 15 | -55 | 21 | 48 |
| 31 Dec 15 | 14 | -48 | 18 | 40 |
| 30 Sep 15 | 13 | -19 | 14 | 29 |
| 30 Jun 15 | 10 | -37 | 10 | 24 |
| 31 Mar 15 | 7 | -16 | 8 | 19 |
| 31 Dec 14 | 4 | -12 | 5 | 16 |
| 30 Sep 14 | 2 | -13 | 4 | 14 |
| 30 Jun 14 | 1 | -12 | 3 | 10 |
Quality Earnings: 473A is currently unprofitable.
Growing Profit Margin: 473A is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 473A is unprofitable, and losses have increased over the past 5 years at a rate of 2.4% per year.
Accelerating Growth: Unable to compare 473A's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 473A is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.9%).
Return on Equity
High ROE: 473A has a negative Return on Equity (-288.19%), as it is currently unprofitable.